Immunohistochemical evaluation of MYC expression in mantle cell lymphoma

Histopathology

Volumn 63, Issue 4, 2013, Pages 499-508

  Oberley, Matthew J ^a   Rajguru, Saurabh A ^a   Zhang, Chong ^a   Kim, Kyungmann ^a,b   Shaw, Gene R ^c   Grindle, Kreg M ^b   Kahl, Brad S ^a,b   Kanugh, Craig ^d   Laffin, Jennifer ^a,d   Yang, David T ^a,b  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF WISCONSIN   (United States)

^c MARSHFIELD CLINIC   (United States)

^d WISCONSIN STATE LABORATORY OF HYGIENE   (United States)

Author keywords

Immunohistochemistry; Mantle cell lymphoma; MYC; Tissue microarray

Indexed keywords

LACTATE DEHYDROGENASE; MESSENGER RNA; MYC PROTEIN;

ADULT; ARTICLE; CANCER SURVIVAL; CLINICAL EVALUATION; CONTROLLED STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; IMMUNOHISTOCHEMISTRY; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MANTLE CELL LYMPHOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; TISSUE MICROARRAY;

IMMUNOHISTOCHEMISTRY; MANTLE CELL LYMPHOMA; MYC; TISSUE MICROARRAY;

ADULT; AGED; AGED, 80 AND OVER; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; KAPLAN-MEIER ESTIMATE; LYMPHOMA, MANTLE-CELL; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS C-MYC; RNA, MESSENGER; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84884705815     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/his.12207     Document Type: Article

References (28)

1. Herrmann A, Hoster E, Zwingers T et al. Improvement of overall survival in advanced stage mantle cell lymphoma. J. Clin. Oncol. 2009; 27; 511-518.
2. Orchard J, Garand R, Davis Z et al. A subset of t(11;14) lymphoma with mantle cell features displays mutated IgVH genes and includes patients with good prognosis, nonnodal disease. Blood 2003; 101; 4975-4981.
3. Martin P, Chadburn A, Christos P et al. Outcome of deferred initial therapy in mantle-cell lymphoma. J. Clin. Oncol. 2009; 27; 1209-1213.
4. Williams ME, Bernstein SH, Jares P, Kahl BS, Witzig TE, Gordon LI. Recent advances in mantle cell lymphoma: report of the 2012 Mantle Cell Lymphoma Consortium Workshop. Leuk. Lymphoma 2013; doi:10.3109/10428194.2013.771400 [Epub ahead of print]
5. Rosenwald A, Wright G, Wiestner A et al. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell 2003; 3; 185-197.
6. Hartmann E, Fernàndez V, Moreno V et al. Five-gene model to predict survival in mantle-cell lymphoma using frozen or formalin-fixed, paraffin-embedded tissue. J. Clin. Oncol. 2008; 26; 4966-4972.
7. Klapper W, Hoster E, Determann O et al. Ki-67 as a prognostic marker in mantle cell lymphoma - consensus guidelines of the pathology panel of the European MCL Network. J. Hematop. 2009; 2; 103-111.
8. Lin CY, Lovén J, Rahl PB et al. Transcriptional amplification in tumor cells with elevated c-Myc. Cell 2012; 151; 56-67.
9. Nie Z, Hu G, Wei G et al. c-Myc is a universal amplifier of expressed genes in lymphocytes and embryonic stem cells. Cell 2012; 151; 68-79.
10. Klapproth K, Wirth T. Advances in the understanding of MYC-induced lymphomagenesis. Br. J. Haematol. 2010; 149; 484-497.
11. Aukema SM, Siebert R, Schuuring E et al. Double-hit B-cell lymphomas. Blood 2011; 117; 2319-2331.
12. Hernández L, Hernández S, Beà S et al. c-myc mRNA expression and genomic alterations in mantle cell lymphomas and other nodal non-Hodgkin's lymphomas. Leukemia 1999; 13; 2087-2093.
13. Au WY, Horsman DE, Viswanatha DS, Connors JM, Klasa RJ, Gascoyne RD. 8q24 translocations in blastic transformation of mantle cell lymphoma. Haematologica 2000; 85; 1225-1227.
14. Hao S, Sanger W, Onciu M, Lai R, Schlette EJ, Medeiros LJ. Mantle cell lymphoma with 8q24 chromosomal abnormalities: a report of 5 cases with blastoid features. Mod. Pathol. 2002; 15; 1266-1272.
15. Au WY, Horsman DE, Gascoyne RD, Viswanatha DS, Klasa RJ, Connors JM. The spectrum of lymphoma with 8q24 aberrations: a clinical, pathological and cytogenetic study of 87 consecutive cases. Leuk. Lymphoma 2004; 45; 519-528.
16. Reddy K, Ansari-Lari M, Dipasquale B. Blastic mantle cell lymphoma with a Burkitt translocation. Leuk. Lymphoma 2008; 49; 740-750.
17. Setoodeh R, Schwarz S, Papenhausen P et al. Double-hit mantle cell lymphoma with MYC gene rearrangement or amplification: a report of four cases and review of the literature. Int. J. Clin. Exp. Pathol. 2013; 6; 155-167.
18. Kienle D, Katzenberger T, Ott G et al. Quantitative gene expression deregulation in mantle-cell lymphoma: correlation with clinical and biologic factors. J. Clin. Oncol. 2007; 25; 2770-2777.
19. Johnson NA, Slack GW, Savage KJ et al. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J. Clin. Oncol. 2012; 30; 3452-3459.
20. Green TM, Young KH, Visco C et al. Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J. Clin. Oncol. 2012; 30; 3460-3467.
21. Tapia G, Lopez R, Muñoz-Mármol AM et al. Immunohistochemical detection of MYC protein correlates with MYC gene status in aggressive B cell lymphomas. Histopathology 2011; 59; 672-678.
22. Ventura RA, Martin-Subero JI, Jones M et al. FISH analysis for the detection of lymphoma associated chromosomal abnormalities in routine paraffin-embedded tissue. J. Mol. Diagn. 2006; 8; 141-151.
23. Hoster E, Dreyling M, Klapper W et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood 2008; 111; 558-565.
24. Ceballos E, Delgado MD, Gutierrez P et al. c-MYC antagonizes the effect of p53 on apoptosis and p21WAF1 transactivation in K562 leukemia cells. Oncogene 2000; 19; 2194-2204.
25. Snuderl M, Kolman OK, Chen YB et al. B-cell lymphoma with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma. Am. J. Surg. Pathol. 2010; 34; 327-340.
26. Kluk MJ, Chapuy B, Sinha P et al. Immunohistochemical detection of MYC-driven diffuse large B-cell lymphomas. PLoS ONE 2012; 7; e33813.
27. Mertz JA, Conery AR, Bryant BM et al. Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proc. Natl Acad. Sci. U S A 2011; 108; 16669-16674.
28. Delmore JE, Issa GC, Lemieux ME et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 2011; 146; 904-917.